The Global Consortium on Immunotherapy:

HIV T-cell Immunotherapy

In 1991, Dr. Jonas Salk proposed an innovative approach in the control of HIV based upon an innovative technique called T-cell vaccination.

 

The T-cell treated patient, while remaining HIV positive, benefits from a 'live and let live' functional cure through immune system support, specifically the re-establishment of immunological memory. The patient remains asymptomatic, perhaps without the need for anti-retrovirals and the associated toxicity issues.

 

The Global Consortium for Immunotherapy, a collaborative effort between Hadassah University Hospital and Human Futures Foundation, was established in support of conducting clinical trials in humans of this ground-breaking immunotherapeutic technique in the treatment of autoimmune diseases including multiple sclerosis, rheumatoid arthritis, and HIV/AIDS through clinical trials in the United States.

 

 

Copyright © 2016 Human Futures Foundation, Inc. All rights reserved. Terms of Use.